Patterns of antibiotics and pathogens for anastomotic leakage after colorectal cancer surgery

Geunhyeok Yang, Chang Woo Kim, Suk-Hwan Lee
Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea

Purpose: Anastomotic leakage (AL) is a type of intra-abdominal infection (IAI) which requires appropriate antibiotics with proper intervention. This study aimed to improve the appropriateness of antibiotic treatment by assessing the patterns of antibiotic treatment and resistance of pathogen profiles in patients who had AL after colorectal cancer surgery.

Methods: From June 2006 through December 2017, the medical records of the patients who had AL after elective abdominal surgery for colorectal cancer in Kyung Hee University Hospital at Gangdong, Seoul, Korea were reviewed retrospectively. Baseline characteristics and consistency of antibiotics with culture study results were analyzed to evaluate the appropriateness of treatment.

Results: Among 982 patients who underwent primary surgery for colorectal cancer, 41 (4.2%) had AL. Mean time of diagnosis of AL from surgery was 6.3 days. The most commonly used prophylactic antibiotics for the primary surgery was 2nd generation cephalosporin (66.6%). Mean duration of prophylactic antibiotics usage was 2.8 days. The most commonly used empirical antibiotics after AL occurred was piperacillin and tazobactam (32.6%). Mean duration of empirical antibiotics usage was 8.2 days. The most commonly identified pathogens were Escherichia coli and Enterococci spp. (26.8% each), and 12.2% of the “ESKAPE” pathogens were identified. Resistance to empirical antibiotics was 45.5% (10/22).

Conclusion: Penetration of culture study for AL after colorectal cancer surgery appeared relatively low, although the profile of pathogens isolated from the AL patients can give important clues and evidence for appropriate antibiotics use. Surgeons should pay attention in performing culture studies for IAI including AL for proper patient treatment.

Keywords: Intraabdominal infection, Antibiotics, Resistance, Colonic neoplasms, Anastomotic leakage

INTRODUCTION

Intra-abdominal infection (IAI) represents a wide variety of patho-
each local region [6-9]. Even some authors made the acronym “ESKAPE” pathogens to emphasize the importance of appropriate antimicrobial therapy despite increasing antibiotic resistance [10].

Anastomotic leakage (AL) after colorectal cancer surgery remains the most feared and disastrous complication for both surgeon and patient, affecting long-term oncologic outcomes as well as frequent need for redo interventions, longer hospitalization, and high mortality rates [11]. AL is also a type of IAI in which the infection source leaks through the intestinal anastomosis for which proper antibiotics is mandatory with proper intervention. In most case of suspected AL, empirical antibiotics are administered targeting the gut flora. However, only a few studies assessed the relevance of antibiotics for AL. This study aimed to improve the appropriateness of antibiotic treatment by assessing the patterns of antibiotic treatment and resistance of pathogen profiles in patients who had AL after colorectal cancer surgery.

METHODS

From June 2006 through December 2017, consecutive patients who underwent elective abdominal surgery for colorectal cancer in our hospital were screened. The medical records of the patients were reviewed retrospectively after approval by the Institutional Review Board (IRB) of Kyung Hee University Hospital at Gangdong (IRB No. KHNMC 2018-08-017). Among the all screened patients, cases of surgery for recurrence or reoperation were excluded. Data of the patients who had AL after primary surgery were reviewed retrospectively.

Eligible patients’ sex, age, height, weight, location of tumor, type of surgery, type and duration of prophylactic antibiotics before surgery, date of AL diagnosed from the day of surgery, white blood cell count (WBC), C-reactive protein (CRP), type of procedure or operation for AL, and time from AL to procedure or surgery were recorded. In addition, results of culture study from the abdominal fluid or abscess after AL was diagnosed, antibiotic resistance, the type and duration of empirical or therapeutic antibiotics administered for the purpose of treatment for AL, hospital stay, and mortality were analyzed.

Location of tumor varied as right colon, left colon, and rectum, and transverse colon cancer was regarded as right side near the proximal part or left side near the distal part. As for data on WBC and CRP, the most recent data from the diagnosis of AL were recorded. Types of source control procedure were classified as follows: percutaneous drainage, surgical drainage, simple closure, surgical drainage and proximal diversion, resection and proximal diversion, resection, and re-anastomosis.

To evaluate the appropriateness of treatment, consistency of antibiotics with culture study results and recurrent infection including surgical site infection (SSI) occurring within 30 days after intervention were analyzed.

RESULTS

During the study period, a total of 982 patients underwent elective surgery for the treatment of primary colorectal cancer. Among them, 41 patients (4.2%) experienced AL (Table 1), and culture studies for intra-abdominal fluid or abscess from AL were performed in 22 patients (53.7%). The most frequent diagnosed site of AL was rectum (n = 29, 70.7%), and 39 of 41 patients underwent intervention for source control whereas two patients were treated with only antibiotics. Source control interventions were performed within 1 day from AL in 19 patients (46.3%).

Surgical drainage and proximal diversion was performed most for source control of AL (n = 23, 56.1%), followed by simple closure (n = 4), resection and proximal diversion (n = 4), percutaneous drainage (n = 3), surgical drainage (n = 3), and resection and re-anastomosis (n = 2).

Table 1. Patients characteristics

| Variable | Value (n = 41) |
|----------|---------------|
| Age (yr) | 62.2 ± 11.3   |
| Male sex | 31 (75.6)     |
| Location of tumor | |
| Right colon | 4 (9.8) |
| Left colon | 8 (19.5) |
| Rectum | 29 (70.7) |
| Duration between surgery and AL (day) | 6.3 (0–27) |
| Characteristics of index infection (AL) | |
| WBC at diagnosis (J/mm³) | 9,737 ± 4,078 |
| CRP at diagnosis (mg/dL) | 16.6 ± 10.2 |
| Culture study performed | 22 (53.7) |
| Source control intervention | 39 (95.1) |
| Duration between AL and intervention | |
| ≤ 1 day | 19 (48.7) |
| > 1 day | 20 (51.3) |
| Intervention type | |
| Percutaneous drainage | 3 (7.3) |
| Surgical drainage | 3 (7.3) |
| Simple closure | 4 (9.8) |
| Surgical drainage and proximal diversion | 23 (56.1) |
| Resection and proximal diversion | 4 (9.8) |
| Resection and re-anastomosis | 2 (4.9) |
| Conservative management | 2 (4.9) |

Values are presented as mean ± standard deviation, number (%), or median (range).

AL, anastomotic leakage; WBC, white blood cell; CRP, C-reactive protein.
### Table 2. Culture result and antibiotics resistance

| Patient | Primary surgery | Prophylactic antibiotics | Empiric antibiotics | Pathogens 1 | Pathogens 2 | Pathogens 3 | Sensitivity | ESKAPE |
|---------|----------------|--------------------------|---------------------|-------------|-------------|-------------|-------------|--------|
| 1       | uLAR           | Ceftriaxone, metronidazole | Ceftezole, metronidazole | *Escherichia coli* | *Streptococcus viridans* group | Sensitive |
| 2       | AR             | Ceftezole, metronidazole | Ceftezole, metronidazole | *Enterococcus faecium* | *Staphylococcus aureus* | Resistant | MRSA |
| 3       | LAR            | Cefotetan, metronidazole | Meropenem, metronidazole | *Staphylococcus aureus* | *Enterococcus faecalis* | Resistant | MRSA |
| 4       | LAR            | Cefminox, metronidazole | Ceftriaxone, metronidazole | *Enterococcus faecium* | *Acinetobacter baumannii* | Resistant | IRAB |
| 5       | LAR            | Cefminox, metronidazole | Cefminox, metronidazole | *Enterococcus faecalis* | *Pseudomonas aeruginosa* | Resistant |
| 6       | LAR            | Cefminox, metronidazole | Cefminox, metronidazole | *Escherichia coli* | *Morganella morganii ssp.* | Sensitive |
| 7       | LAR            | Cefotetan | Meropenem | *Morganella morganii ssp.* | Sensitive |
| 8       | LAR            | Cefotetan | Ceftriaxone, metronidazole | *Klebsiella pneumoniae* ssp. *Escherichia coli* | *Enterococcus faecium* | Resistant |
| 9       | LAR            | Cefotetan | Pipertacillin/ tazobactam, levofoxacin | *Pseudomonas aeruginosa* | *Enterococcus faecium* | Resistant |
| 10      | RHC            | Cefotetan | Pipertacillin/ tazobactam | *Pseudomonas aeruginosa* | *Klebsiella pneumoniae* | Sensitive |
| 11      | LAR            | Cefotetan | Pipertacillin/ tazobactam, metronidazole | No growth | unknown |
| 12      | LAR            | Cefotetan | Cefotetan | *Pseudomonas aeruginosa* | *Enterococcus avium* | Resistant |
| 13      | uLAR           | Cefotetan | Cefotetan, metronidazole | *Escherichia coli* | *Streptococcus viridans* | Sensitive |
| 14      | RHC            | Cefotetan | Cefotetan | *Escherichia coli* | *Klebsiella oxytoca* | β-Hemolytic streptococcus, group G | Sensitive |
| 15      | LAR            | Cefotetan | Cefminox, metronidazole | *Enterococcus faecalis* | *Pseudomonas aeruginosa* | Resistant |
| 16      | LAR            | Cefotetan | Pipertacillin/ tazobactam | *Staphylococcus aureus* | *Stenotrophomonas maltophilia* | Resistant | MRSA |
| 17      | LAR            | No | No | *Escherichia coli* | Unknown | ESBL+ |
| 18      | LAR            | Cefotetan | Moxifloxacin | *Escherichia coli* | Sensitive |
| 19      | TC             | Cefotetan | Pipertacillin/ tazobactam | *Escherichia coli* | Sensitive |
| 20      | uLAR           | Cefotetan | Pipertacillin/ tazobactam | *Escherichia coli* | *Enterococcus faecalis* | Sensitive |
| 21      | LAR            | Cefotetan | Pipertacillin/ tazobactam | *Klebsiella pneumoniae* | *Escherichia coli* | Sensitive |
| 22      | ERHC           | Cefotetan | Pipertacillin/ tazobactam, levofoxacin | *Enterococcus faecium* | *Escherichia coli* | Resistant |

LAR, low anterior resection; uLAR, ultra-low anterior resection; AR, anterior resection; RHC, right hemicolectomy; TC, total colectomy; ERHC, extended right hemicolectomy; MRSA, methicillin-resistant *S. aureus*; IRAB, imipenem-resistant *A. baumannii*; ESBL+, extended-spectrum beta-lactamase positive.
Antibiotic use and the results of culture study for pathogens from intra-abdominal samples are listed in Table 2. Except for one patient in which no bacteria grew, 11 kinds, 41 (duplicate) pathogens were identified in 21 patients, and approximately two kinds of bacteria were found per patient. Escherichia coli and Enterococcus spp. (26.8% each) were the most frequently identified, followed by Pseudomonas aeruginosa (12.2%). Twelve point one percent of the “ESKAPE” pathogens were identified including methicillin-resistant Staphylococcus aureus (MRSA) (7.3%), extended-spectrum beta-lactamase (ESBL)-producing E. coli (2.4%), and imipenem-resistant Acinetobacter baumannii (IRAB) (2.4%) [12].

Pathogens identified were described in Table 3. Resistant rates of each pathogen show a wide spectrum from 9.1% to 100%. Resistant rates of MRSA (3/3), IRAB (1/1) were reported as 100%. Resistant rates of ESBL-producing E. coli isolates comprised 9.1% (1/11) of all E. coli isolates.

Table 3. Pathogens identified from intra-abdominal samples

| Pathogens               | No. (%)          | Resistance (%) |
|-------------------------|------------------|----------------|
| Gram (+) Aerobic        |                  |                |
| Staphylococcus aureus   | MSSA 3 (7.3)     | 100            |
| MRSA 3 (7.3)            |                  |                |
| Streptococcus spp.      | 3 (7.3)          |                |
| Enterococcus faecalis   | 5 (12.2)         |                |
| Enterococcus avium      | 1 (2.4)          |                |
| Enterococcus faecium    | 5 (12.2)         |                |
| Anaerobic               |                  |                |
| Escherichia coli        | ESBL (-) 10 (24.4) |                |
| ESBL (+) 1 (2.4)        | 9.1%            |
| Klebsiella spp.         | ESBL (-) 4 (8.8) |                |
| ESBL (+) NA             |                |
| Enterobacter aerogenes  | ISPA 5 (12.2)    |                |
| Pseudomonas aeruginosa  | IRPA NA         |                |
| Acinetobacter baumannii| ISAB            |                |
| IRAB 1 (2.4)            | 100             |
| Proteus mirabilis       | NA              |                |
| Stenotrophomonas maltophilia| 1 (2.4) |                |
| Morganella morganii     | 2 (4.9)         |                |
| Anaerobic Bacteroides   | NA              |                |

MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S. aureus; ESBL, extended-spectrum beta-lactamase; ISPA, imipenem-sensitive P. aeruginosa; IRPA, imipenem-resistant P. aeruginosa; ISAB, imipenem-sensitive A. baumannii; IRAB, imipenem-resistant A. baumannii; NA, not available.

Table 4. Prophylactic antibiotics for colorectal cancer surgery

| Antibiotics agent | No. (%) |
|-------------------|---------|
| Cephalosporin     |         |
| 1st G Cephalosporin+MTD 1 (2.4) |         |
| 2nd G Cephalosporin only 28 (68.3) |         |
| 2nd G Cephalosporin+MTD 4 (9.8) |         |
| 3rd G Cephalosporin+MTD 6 (14.6) |         |
| No antibiotics    | 2 (4.9) |

G, generation; MTD, metronidazole.

Table 5. Empiric therapeutic antibiotics

| Antibiotics agent | No. (%) |
|-------------------|---------|
| Penicillins/β-lactamase inhibitors | Piperacillin/tazobactam 14 (32.6) |         |
| Carbapenems       | Meropenem 1 (2.3) |         |
| Fluoroquinolones  | Levofloxacin 2 (4.7) |         |
|                   | Moxifloxacin 3 (7.0) |         |
| Cephalosporin     | 1st G Cephalosporin+MTD 1 (2.3) |         |
|                   | 2nd G Cephalosporin only 8 (18.6) |         |
|                   | 2nd G Cephalosporin+MTD 5 (11.6) |         |
|                   | 3rd G Cephalosporin+MTD 5 (11.6) |         |
| No antibiotics    | 4 (9.3) |

G, generation; MTD, metronidazole.

Antibiotic use and the results of culture study for pathogens from intra-abdominal samples are listed in Table 2. Except for one patient in which no bacteria grew, 11 kinds, 41 (duplicate) pathogens were identified in 21 patients, and approximately two kinds of bacteria were found per patient. Escherichia coli and Enterococcus spp. (26.8%) were the most frequently identified, followed by Pseudomonas aeruginosa (12.2%). Twelve point one percent of the “ESKAPE” pathogens were identified including methicillin-resistant Staphylococcus aureus (MRSA) (7.3%), extended-spectrum beta-lactamase (ESBL)-producing E. coli (2.4%), and imipenem-resistant Acinetobacter baumannii (IRAB) (2.4%) [12].

Pathogens identified were described in Table 3. Resistant rates of each pathogen show a wide spectrum from 9.1% to 100%. Resistant rates of MRSA (3/3), IRAB (1/1) were reported as 100%. Resistant rates of ESBL-producing E. coli isolates comprised 9.1% (1/11) of all E. coli isolates.

Prophylactic antibiotics administration was confined to the cephalosporins for 39 of 41 patients and combined with metronidazole in 11 patients (26.2%) (Table 4). Two patients were not administered prophylactic antibiotics because they were already being treated with therapeutic antibiotics that focused on underlying infectious disease. The mean duration of administration was 2.8
days, but the duration of prophylactic antibiotic treatment for the last 5 years was 1.1 days. This is in accordance with the trend of recent guideline for prophylactic antibiotic in surgery, which recommended that the postoperative duration of antimicrobial prophylaxis can be reduced [13,14].

The prescribed therapeutic empiric antibiotics patterns are listed in Table 5. Of the 43 antibiotics including overlapping, 14 (32.6%) piperacillin/tazobactam were administered and eight 2nd generation cephalosporin only (18.6%), and five 2nd and 3rd generation cephalosporin plus metronidazole, fluoroquinolone (11.6% each) were administered. Carba penem was given only for one patient (2.3%). Glycopeptides (Vancomycin) and Glycyclines (Tigecyclin) were never used as empirical antibiotics. On the other hand, no antibiotics were prescribed to four patients (9.3%) because the symptoms of AL were relatively mild for those patients.

Mean duration of empirical antibiotics use were 8.2 days (Table 6), which is similar with the recommendations of recent guidelines [15]. In-hospital mortality rate was 2.4% and cause of death was sepsis. Mean hospital stay was 29.4 days (range, 10–68 days). Fourteen patients (34.1%) had recurrent infection including SSI after source control. In 10 of 22 patients (45.5%) who had culture study, identified pathogens were reported to be resistant to the given empirical antibiotics (Table 2).

DISCUSSION

Secondary peritonitis is a consequence of a mechanical breach of the gastrointestinal tract. The microbial species isolated reflect the patterns of colonization of the involved level of the gastrointestinal tract: perforation of the stomach or duodenum results in an inflammatory process that is primarily chemical, whereas perforations of the colon create polymicrobial infections including AL after colorectal cancer surgery [16]. It explains the importance of knowledge on organ origin of infection because it helps clinicians choose the appropriate treatment, including selection of antibiotics.

The authors assessed the pathogens from the infected source from AL after colorectal cancer surgery and found a relatively low proportion of culture study performance (22/41, 53.7%) and appropriate antibiotics according to antibiotic resistance (12/22, 54.5%).

Although only 4.2% of AL was reported after overall colorectal cancer surgery, it scarcely occurred in right colon cancer surgery. When limited to left colon or rectal cancer surgery, 37 of 389 patients (9.5%) had AL after primary surgery.

We reviewed empirical antibiotics prescription pattern and infection severity with these patients. Only 22 patients (53.7%) had culture study from the intraperitoneal source (abscess or fluid) and the pathogens were identified from 21 patients. This low performance of culture study might be due to lack of interest by surgeons, rather than lack of time. Moreover, although most of the pathogens are expected to be gut flora (possibly one of the reasons culture studies were not performed), the authors found that proper antibiotics use rates were only 54.5% considering antibiotic resistance (Table 2).

The pathogen distribution identified in this study was slightly different from previous reports. Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) provide the best available evidence for the current status of complicated IAIs in Asia [17,18]. Over the course of the SMART, the five most commonly isolated Gram-negative pathogens from IAIs were E. coli (47.8%), Klebsiella pneumoniae (14.5%), P. aeruginosa (9.4%), Enterobacter cloacae (6.0%), and Proteus mirabilis (3.6%) [19]. The CI-AOW (Complicated intra-abdominal infections worldwide observational study) collected the data from 1898 patients in 68 medical institutions worldwide [19]. From the study, the top pathogens from IAIs were E. coli (35.7%), Enterococcus (12.9%), Klebsiella (10.5%), P. aeruginosa (5.1%), Enterobacter spp. (4.1%). In our study, Gram-positive microbe was 41.5% of all pathogens identified. Enterococcus was found to be 26.8% the same as E. coli, and S. aureus was as much as 7.3%. Regarding resistance, it is remarkable that MRSA was identified in 100% of all S. aureus (4/4).

Rice [10], in 2008, coined the acronym of “ESKAPE” pathogens including Enterococcus faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species to emphasize that these bacteria currently cause the majority of hospital infections and effectively “escape” the effects of antibacterial drugs [20]. Published surveillance studies have consistently reported that Gram-negative bacilli, including ESKAPE pathogens, isolated from patients in several countries within the Asia-Pacific region, generally demonstrate higher rates of antimicrobial resistance than observed in North American and European studies, and that the majority of pathogens isolated from intensive care units in a number of Asia-Pacific countries are members of the ESKAPE group.

Table 6. Outcome measurement

| Variable               | Value |
|------------------------|-------|
| Primary outcome        |       |
| Antibiotics use period (day) | 8.2 ± 7.9 |
| Mortality              | 1 (2.4) |
| Hospital stay (day)    | 29.4 ± 15.5 |
| Secondary outcome      |       |
| Recurrent infection    | 14 (34.1) |

Values are presented as mean ± standard deviation or number (%). *Including surgical site infection.
AL belongs to the category of hospital acquired (HA)-IAI and the pathogen spectrum is different from those of community acquired-IAI. For this reason, treatment of AL patients should be administration of broad antibiotics, as in the treatment of HA-IAI patients, with an understanding of pathogen patterns in the region, and the selection of antibiotics to cover the resistant strains accordingly. Especially, it is recommended to consider prescribing agents covering MRSA when clinicians treat the secondary peritonitis caused by colon and rectum in this region due to higher rates of MRSA identification than other guidelines.

Regarding behavior of antibiotics prescription in accordance with published guidelines, it could be considered that 54.5% of 41 patients were prescribed appropriately with narrow-spectrum antibiotics. Broad-spectrum antibiotics such as piperacillin/tazobactam or carbapenem should have been prescribed for HA-IAI such as AL patients, and narrow-spectrum antibiotics, which can resist ESKEAPE strains, should have been avoided [6,8,9].

There are several limitations in this study. Selection bias from the retrospective nature is inevitable. Moreover, culture study of pathogens, which is the most important procedure in this study, was performed only in about half of the patients with AL. Lastly, consistency of prophylactic and empirical antibiotic use lack regarding both kind and duration of antibiotics.

In conclusion, penetration of culture study for AL after colorectal cancer surgery appears relatively low, although the profile of pathogens isolated from AL patients can give important clues and evidence for appropriate antibiotics use. Surgeons should pay attention in performing culture studies for IAI including AL to treat patients with the proper method without wasting time and cost. Further studies are required to update the current status and problems of antibiotics use.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government Ministry of Education (No. 017R1D1A1B03030948).

REFERENCES

1. Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemother 2009;21 Suppl 1:3-4.
2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015;40:277-83.
3. Ventola CL. The antibiotic resistance crisis: part 2: management strategies and new agents. P T 2015;40:344-52.
4. Strukkenboom MC, Goettsch WG, Picelli G, in’t Veld B, Yin DD, de Jong RB, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005;60:438-43.
5. Solomon SL, Oliver KB. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician 2014;89:938-41.
6. Mazuski JE, Tessler JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The surgical infection society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt) 2017;18:1-76.
7. Sartelli M, Weber DG, Ruppe E, Bassetti M, Wright BJ, Ansaloni L, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg 2016;11:33.
8. Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, et al. 2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg 2013;8:3.
9. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64.
10. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKEAPE. J Infect Dis 2008;197:1079-81.
11. Hammond J, Lim S, Wan Y, Gao X, Patkar A. The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes. J Gastrointest Surg 2014;18:1176-85.
12. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg 2014;9:37.
13. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013;14:73-156.
14. Park YY, Kim CW, Park SJ, Lee KY, Lee JJ, Lee HO, et al. Influence of shorter duration of prophylactic antibiotic use on the incidence of surgical site infection following colorectal cancer surgery. Ann Coloproctol 2015;31:235-42.
15. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015;372:1996-2005.
16. Marshall JC. Intra-abdominal infections. Microbes Infect 2004;6:1015-25.
17. Hsueh PR. Study for monitoring antimicrobial resistance trends (SMART) in the Asia-Pacific region, 2002-2010. Int J Antimicrob Agents 2012;40 Suppl:S1-3.
18. Chow JW, Satishchandran V, Snyder TA, Harvey CM, Friedland I.R, Dinubile MJ. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2005;6:439-48.
19. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013;6:1335-46.
20. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice I.B, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
21. Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GIL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73.
22. Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the study for monitoring antimicrobial resistance trends (SMART). Int J Antimicrob Agents 2012;40 Suppl:S37-43.